Aetna, Cigna and UnitedHealthcare are enhancing their Medicare pharmacy benefits, including offering insulin for a copay of no more than $35 for a 30-day supply.
Formulary Watch
Latest News
All News
Advertisement
Given together, bamlanivimab and etesevimab have an emergency use authorization from the FDA to both treat COVID-19 and prevent infection in those who have been exposed.
Livmarli is the first drug approved for Alagille syndrome.
Effective Oct. 1, 2021, Aetna has added several cancer drugs to its formulary and has updated exclusions and nonpreferred products.
Comprehensive medication management aided by AI clinical decision support can result in a large return on investment in a high-risk population. In this study, every dollar that was invested resulted in $12 in savings or cost avoidance.
Trudhesa was approved in September to treat migraine.
The company has also launched a website for patients affected by hereditary angioedema, a rare genetic disorder.
Half of the 14 oncology indications approved in the second quarter were accelerated approvals.
This is the seventh approval for Erbitux and the only anti-EGFR antibody approved for this indication.
Advertisement
The enzyme replacement therapy treats Pompe disease, a rare genetic disorder that affects children.
The PDUFA target action date for the FDA decision is Jan. 30, 2022.
Data is being presented at the 10th Annual IDWeek Virtual Conference, September 29 to October 3.
AbbVie’s Qulipta is a once-daily oral to prevent migraines in adults.
The companies plan to request an emergency use authorization in a few weeks.
The companies are seeking accelerated approval based on the surrogate end point of beta amyloid reduction.
The flu program is the first in programs leveraging BioNTech’s mRNA technology for vaccines for other respiratory viruses, oncology, and genetic diseases.
Effective Jan. 1 2022, the move brings the price to 2008 levels.
Prices paid by Veterans Affairs were the lowest and were 50% to 60% below list prices.
The FDA assigned a Prescription Drug User Fee Act goal date of May 28, 2022.
Repatha is now available for children 10 and older to lower low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.
The diabetes therapy is being recalled because of a lack of potency.
Amgen’s Biosimilar Trend Report finds that biosimilars have been introduced at a price that is generally 15% to 37% lower than the reference product.
Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.
Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations.
Advertisement
Advertisement